May 29, 2026

Cutting-edge AI is great, but how will your health system pay for it?

Optellum is the only Lung Nodule AI with named reimbursement by CMS 5 years and running. ^{1, 2, 3, 4, 5}

Our US health system partners are billing and being reimbursed for using Optellum’s Lung Cancer Prediction (LCP) AI today. We help remove the financial risks often associated with cutting-edge AI adoption. While other tools offer promises, Optellum delivers.

That’s why leading pulmonary, thoracic oncology, and radiology programs across the US choose Optellum to help drive earlier diagnoses, service line growth, and more confident Lung Cancer Care decisions. ⁶

Learn more, visit our Reimbursement page

Sources:

[1] 2026 HOPPS
[2] 2025 HOPPS
[3] 2024 HOPPS
[4] 2023 HOPPS
[5] 2022
[6] Optellum publications page

Recent posts

May 20, 2026

Earlier detection meets the clock: When the 8-week window to surgery can...

May 18, 2026

Optellum Virtual Nodule Clinic (VNC) vs. RevealDx RevealAI-Lung

May 17, 2026

Lung nodule care doesn’t stop at the radiology report. So why should...

May 20, 2026

Earlier detection meets the clock: When the 8-week window to surgery can make or break lung cancer survival

In this next topic of our Learning Center Highlight series, we’ll explore why the time between detecting a lung nodule and taking action matters more than ever in lung cancer survival.

May 18, 2026

Optellum Virtual Nodule Clinic (VNC) vs. RevealDx RevealAI-Lung

Incidental lung nodule care requires more than a one-time risk output. Thoracic programs are multidisciplinary teams comprising pulmonologists, radiologists,...

May 17, 2026

Lung nodule care doesn’t stop at the radiology report. So why should the AI?

Incidental lung nodules are managed by multidisciplinary teams, not one specialty alone. Our LCP AI remains the only FDA-cleared AI risk stratification solution indicated for both pulmonologists and radiologists.